Haven Private’s AbbVie ABBV Stock Holding History

Haven Private’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,182	Closed	-$219K	–	154
2025 Q2	$219K	Buy	+1,182	New	+$220K	0.1%	165

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Haven Private's ABBV Position: Q3 2025 in Review

Haven Private sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 1,182 shares — an estimated $219K sold.

Haven Private first reported a position in ABBV in Q2 2025 and held it in 1 quarter. The position peaked at $219K in Q2 2025. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Haven Private reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
Haven Private sold 1,182 AbbVie shares in Q3 2025, an estimated $219K.
Haven Private first reported a position in AbbVie in Q2 2025 and held it in 1 quarter.
Haven Private's AbbVie position peaked at $219K in Q2 2025.
3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Haven Private's 13F filing for Q3 2025, filed 6 Nov 2025.